Sponsor(s): Medical Research Council Technology

Opportunities for commercialising drug discovery in the academic sector

SCI HQ, London, UK
17 February 2011, 09.30 - 18.30
Organised by SCI's Science and Enterprise Group

Synopsis

The aim of this event is to highlight the apparent development gap that exists between academia and the pharmaceutical industry and to discuss mechanisms by which this gap can be bridged. Topics include the development of partnerships between academia/industry, sources of funding and the current investment climate. Case studies will be used as examples throughout the day. Representatives from both the academic and pharmaceutical sectors will be in attendance to share their insights, with networking opportunities available.

Who should attend

This one day conference is for anyone involved with the development of early stage drug discovery opportunities, including technology transfer representatives and researchers. In addition, this event will be of interest to individuals from the pharmaceutical industry associated with the identification and licensing of projects from academia and the promotion of external alliances.

Programme

Please click here to view the full programme.

 

09.30

 

Registration and refreshments

10.00

 

Welcome

10.10

 

Facilitating partnerships between pharma and academia
Dr Alan Lamont, AstraZeneca

10.45

 

The Imperial Drug Discovery Centre; enabling translation of academic projects towards commercial reality
Dr Cathy Tralau-Stewart, Imperial College Drug Discovery Centre

11.20  

Refreshment break

11.40  

Commercialising IP the Oxford Way
Ms Linda Naylor, Oxford University

12.15  

Thiakis: from conception to exit
Prof Steve Bloom, Imperial College and Thiakis founder

12.50  

Lunch (kindly sponsored by MRCT)

13.50  

The Role of Public � Private partnerships in Pharmaceutical R&D
Dr Dave Tapolczay, MRCT

14.25  

Wellcome Trust approaches to support innovative drug discovery
Dr Richard Davis, Wellcome Trust

15.00  

Refreshment break

15.20  

Mordern Biosciences: development of late-stage discovery projects from academia
Dr Sam Williams, Modern Biosciences�

 

15.55  

Investment in drug discovery... does it make sense? and who are the investors?
Dr Andy Richards, Business Angel

16.30  

Wine reception and networking

Organising Committee

Dr Kirsty Hewitson, Union Life Sciences Ltd
Dr David Lawrence, Syngenta Ltd
 

Location

SCI HQ, London, UK
Please click here for a location map.
 

Delegate Fees

Please note fees include the 5% discount for making an online booking

Earlybird fees - before 17 January
GB�90.00 . . . . . . . . . SCI Member
GB�30.00 . . . . . . . ... SCI Student
GB�60.00 . . . . . . . ... Subsidised Member
GB�120.00 . . . . . . . . Non Member
 

Standard fees - after 17 January
GB�105.00 . . . . . . . . SCI Member
GB�35.00 . . . . . . . . ..SCI Student
GB�70.00 . . . . . . . . . Subsidised Member
GB�140.00 . . . . . . . . Non Member
 

With thanks to our Sponsor:

��

MRC Technology works with scientists from Medical Research Council-funded Units and collaborating organisations to discover and protect healthcare innovations. They combine technology transfer, small molecule drug discovery and therapeutic antibody functions in order to convert knowledge into commercial success.
 

For more information, please contact:

Conference Team
T: +44 (0)20 7598 1561
F: +44 (0)20 7235 7743
E: conferences@soci.org

---

Topic:

celebrating chemistry, conferences, chemistry education, networking

Audience:

students, professional chemists, educators, industrial chemists, professors, general public, universities, post graduate students, decision makers, research scientists, women chemists

Want to submit your own activity or comment?

In order to do so you need to be part of the IYC network. Please log in or sign up now.

Join the IYC Network